Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model
LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
The Phase 1 study, a non-randomised, open-label, multicentre trial, is evaluating IKS014 in patients with locally advanced or metastatic solid tumours expressing HER2
The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas
Harbour BioMed brings advanced antibody discovery platforms to the table
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region
Angelini Ventures has already invested €125 million in 22 startups
GV20 received an upfront payment and is eligible for additional milestone payments
Subscribe To Our Newsletter & Stay Updated
